FindTrial
Sign In

[18F]APN-1607

DRUG3 trials

Sponsors

APRINOIA Therapeutics, LLC, Nanjing First Hospital, Nanjing Medical University, APRINOIA Therapeutics

Conditions

Alzheimer DiseaseAlzheimer's DiseaseHealthy VolunteersMild Cognitive Impairment Due to Alzheimer's Disease

Early Phase 1

Clinical Evaluation of [18F]APN-1607 PET Uptake in Alzheimer's Disease Patients
NCT05043675
Nanjing First Hospital, Nanjing Medical UniversityAlzheimer Disease
Start: 2021-09-10End: 2024-09-10Target: 6Updated: 2023-09-14

Phase 2

Evaluation of [18F]APN-1607 PET Uptake in Alzheimer's Disease Patients Compared With Healthy Subjects
NCT04141150
APRINOIA Therapeutics, LLCAlzheimer's Disease, Healthy Volunteers, Mild Cognitive Impairment Due to Alzheimer's Disease
Start: 2022-03-22End: 2025-02-28Target: 130Updated: 2023-06-15

Phase 3

[18F]APN-1607 PET in Subjects With AD Compared to HC
CompletedNCT05542953
APRINOIA TherapeuticsAlzheimer's Disease, Healthy Volunteers, Mild Cognitive Impairment Due to Alzheimer's Disease
Start: 2022-01-21End: 2023-12-25Updated: 2025-09-08